Skip to content

Neuropharmacology

ISSN 1873-7064

241 papers in the library · 4,645 citations · publishing 1982-2026

Papers

Sort Most recent Most cited

The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue.

Neuropharmacology February 2016 Julie A. Marusich, Kateland R Antonazzo, Bruce E. Blough et al.

In recent years, use of psychoactive synthetic stimulants has grown rapidly. 5-(2-Aminopropyl)indole (5-IT) is a synthetic drug associated with a number of fatalities, that appears to be one of the newest 3,4-methylenedioxymethamphetamine (MDMA) replacements. Here, the monoamine-releasing properties of 5-IT, its structural isomer 6-(2-aminopropyl)indole (6-IT), and MDMA were compared using in...

DOI: 10.1016/j.neuropharm.2015.09.004 (opens in new tab) Full text (opens in new tab) 3,4-Methylenedioxymethamphetamine MDMA 5-2-aminopropylindole 5-it 6-2-aminopropylindole 6-it Locomotor activity +2

Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus.

Neuropharmacology January 2016 Toshihiro Nomura, Yoshihiro Oyamada, Herman B Fernandes et al.

Repeated administration of non-competitive N-methyl-d-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP) to rodents causes long-lasting deficits in cognition and memory, and has effects on behaviors that have been suggested to be models of the cognitive impairment associated with schizophrenia (CIAS). Despite this being a widely studied animal model, little is known about the...

DOI: 10.1016/j.neuropharm.2015.04.012 (opens in new tab) Full text (opens in new tab) Gaba Hippocampus Inhibitory postsynaptic current Long-term potentiation +1

Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).

Neuropharmacology December 1, 2015 Anna Rickli, Dino Luethi, Julian Reinisch et al. 216 citations

N-2-methoxybenzyl-phenethylamines (NBOMe drugs) are newly used psychoactive substances with poorly defined pharmacological properties. The aim of the present study was to characterize the receptor binding profiles of a series of NBOMe drugs compared with their 2,5-dimethoxy-phenethylamine analogs (2C drugs) and lysergic acid diethylamide (LSD) in vitro. We investigated the binding affinities of...

DOI: 10.1016/j.neuropharm.2015.08.034 (opens in new tab) Full text (opens in new tab) Affinity Hallucinogens Novel psychoactive substances Phenethylamines +1

Noribogaine is a G-protein biased κ-opioid receptor agonist.

Neuropharmacology December 1, 2015 Émeline L. Maillet, Nicolas Milon, Mari D. Heghinian et al. 59 citations

Noribogaine is the long-lived human metabolite of the anti-addictive substance ibogaine. Noribogaine efficaciously reaches the brain with concentrations up to 20 μM after acute therapeutic dose of 40 mg/kg ibogaine in animals. Noribogaine displays atypical opioid-like components in vivo, anti-addictive effects and potent modulatory properties of the tolerance to opiates for which the mode of...

DOI: 10.1016/j.neuropharm.2015.08.032 (opens in new tab) Full text (opens in new tab) 18-mc Analgesia Beta-arrestin pathway Biased agonist +19

Intravenous self-administration of entactogen-class stimulants in male rats.

Neuropharmacology December 2015 Sophia A. Vandewater, Kevin M Creehan, Michael A. Taffe

The intravenous self-administration (IVSA) of 3,4-methylenedioxymethamphetamine (MDMA) is inconsistent in rats, with up to half of subjects failing to acquire reliable drug intake. It is unknown if this changes under long-access conditions (6 h sessions) under which the IVSA of cocaine and methamphetamine escalates. The entactogen class cathinone stimulants which exhibit MDMA-like monoamine...

Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor.

Neuropharmacology December 1, 2015 Kinga Sałat, Agata Siwek, G. Starowicz et al.

Ketamine produces rapid and long-lasting antidepressant effects in patients. The involvement of ketamine metabolites in these actions has been proposed. The effects of ketamine and its metabolites norketamine and dehydronorketamine on ligand binding to 80 receptors, ion channels and transporters was investigated at a single concentration of 10 μM. The affinities of all three compounds were then...

BDNF — a key transducer of antidepressant effects

Neuropharmacology November 11, 2015 C. Björkholm, L. Monteggia

How do antidepressants elicit an antidepressant response? Here, we review accumulating evidence that the neurotrophin brain-derived neurotrophic factor (BDNF) serves as a transducer, acting as the link between the antidepressant drug and the neuroplastic changes that result in the improvement of the depressive symptoms. Over the last decade several studies have consistently highlighted BDNF as...

MAM-2201, a synthetic cannabinoid drug of abuse, suppresses the synaptic input to cerebellar Purkinje cells via activation of presynaptic CB1 receptors.

Neuropharmacology August 2015 Tomohiko Irie, Ruri Kikura-Hanajiri, Makoto Usami et al.

Herbal products containing synthetic cannabinoids-initially sold as legal alternatives to marijuana-have become major drugs of abuse. Among the synthetic cannabinoids, [1-(5-fluoropentyl)-1H-indol-3-yl](4-methyl-1-naphthalenyl)-methanone (MAM-2201) has been recently detected in herbal products and has psychoactive and intoxicating effects in humans, suggesting that MAM-2201 alters brain...

DOI: 10.1016/j.neuropharm.2015.02.025 (opens in new tab) Full text (opens in new tab) Cerebellum Mam-2201 Neurotransmitter release Purkinje cell +1

Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.

Neuropharmacology August 2015 A Vigolo, Andrea Ossato, Claudio Trapella et al.

JWH-018 is a synthetic CB1 and CB2 agonist illegally marketed as products named "Spice" or "herbal blend" for its psychoactive effects which are much higher than those produced by cannabis. In the last year, the European Monitoring Centre for Drugs and Drug Addiction reported to the Italian National Early Warning System the seizure of plant material containing new halogenated derivatives of...

DOI: 10.1016/j.neuropharm.2015.02.008 (opens in new tab) Full text (opens in new tab) Cb1 receptor Jwh-018 pubchem cid Jwh-018 br Jwh-018 cl +2

Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain

Neuropharmacology July 18, 2015 Aisling Spain, Clare Howarth, Alexandre A. Khrapitchev et al. 45 citations

The development of pharmacological magnetic resonance imaging (phMRI) has presented the opportunity for investigation of the neurophysiological effects of drugs in vivo. Psilocin, a hallucinogen metabolised from psilocybin, was recently reported to evoke brain region-specific, phMRI signal changes in humans. The present study investigated the effects of psilocin in a rat model using phMRI and...

Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds.

Neuropharmacology June 2015 Claudia Rangel-Barajas, Maninder Malik, Robert H Mach et al.

We recently reported on the characterization of the hallucinogen 2,5-dimethoxy-4-methylamphetamine's (DOI) ability to elicit a head twitch response (HTR) in DBA/2J mice and the ability of D2 vs. D3 dopamine receptor selective compounds to modulate that response. For these studies, the ability of D3 vs. D2 dopamine receptor selective compounds to attenuate the DOI-dependent HTR was examined. WC...

DOI: 10.1016/j.neuropharm.2014.10.030 (opens in new tab) Full text (opens in new tab) 5-ht2 receptor agonist Antipsychotic D3 dopamine receptors Doi +2

Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.

Neuropharmacology June 2015 D Matthew Walentiny, Robert E Vann, Jenny L Wiley

A number of studies have examined the ability of the endogenous cannabinoid anandamide to elicit Δ(9)-tetrahydrocannabinol (THC)-like subjective effects, as modeled through the THC discrimination paradigm. In the present study, we compared transgenic mice lacking fatty acid amide hydrolase (FAAH), the enzyme primarily responsible for anandamide catabolism, to wildtype counterparts in a THC...

DOI: 10.1016/j.neuropharm.2015.02.004 (opens in new tab) Full text (opens in new tab) 2-arachidonoylglycerol Anandamide Drug discrimination Rimonabant +1

Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Neuropharmacology February 1, 2015 Xi-Ling Jiang, Hong-Wu Shen, Ai-Ming Yu 26 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and harmaline are serotonin (5-HT) analogs often abused together, which alters thermoregulation that may indicate the severity of serotonin toxicity. Our recent studies have revealed that co-administration of monoamine oxidase inhibitor harmaline leads to greater and prolonged exposure to 5-HT agonist 5-MeO-DMT that might be influenced by cytochrome...

DOI: 10.1016/j.neuropharm.2014.10.013 (opens in new tab) Full text (opens in new tab) Thermoregulation Temperature control Thermal regulation Drug interaction +13

(±)3,4-methylenedioxyamphetamine inhibits the TEA-sensitive K⁺ current in the hippocampal neuron and the Kv2.1 current expressed in H1355 cells.

Neuropharmacology February 2015 Chia-Hsien Lin, Chin-Tsang Yang, Ming-Cheng Tsai et al.

The whole-cell patch clamp method was used to study the effects of (±)3,4-methylenedioxyamphetamine (MDA) in hippocampal CA1 neurons from neonatal rats and in lung epithelial H1355 cells expressing Kv2.1. Extracellular application of MDA (30 μM) induced bursts of action potentials in hippocampal CA1 neurons exhibiting single spike action potentials without a bursting firing pattern, and...

DOI: 10.1016/j.neuropharm.2014.09.009 (opens in new tab) Full text (opens in new tab) ±3,4-methylenedioxyamphetamine Action potentials Hippocampal neuron K+ current

Intravenous self-administration of mephedrone, methylone and MDMA in female rats

Neuropharmacology January 17, 2015 Kevin M Creehan, Sophia A. Vandewater, Michael A. Taffe 98 citations

Male rats will intravenously self-administer (IVSA) the substituted cathinone stimulants (“bath salts”) mephedrone (4-methylmethcathione) and methylone (3,4-methylenedioxymethcathinone) robustly, whereas the IVSA of 3,4-methylenedioxymethamphetamine (MDMA) is inconsistent in many rat models. There are no data available on the self-administration of these drugs in female rats, thus a study was...

Memory and mood during MDMA intoxication, with and without memantine pretreatment.

Neuropharmacology December 2014 E B De Sousa Fernandes Perna, E L Theunissen, K P C Kuypers et al.

Previous studies have shown that single doses of MDMA can affect mood and impair memory in humans. The neuropharmacological mechanisms involved in MDMA-induced memory impairment are not clear. Memantine, an NMDA and alpha 7 nicotinic acetylcholine (ACh) receptor antagonist, was able to reverse MDMA-induced memory impairment in rats. This study investigated whether treatment with memantine can...

Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine.

Neuropharmacology December 2014 Esther O'Shea, Andrés Urrutia, Alfred Richard Green et al.

The blood-brain barrier (BBB) is essential in the maintenance of brain homeostasis both by preserving normal brain functioning and also by protecting the brain from exposure to a range of potentially harmful substances. This review presents some of the evidence of BBB disruption following exposure to the substituted amphetamines 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and...

DOI: 10.1016/j.neuropharm.2014.02.015 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxymethamphetamine Basal lamina proteins Blood–brain barrier disruption Igg extravasation +1

Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.

Neuropharmacology November 1, 2014 Bronwyn M Kivell, Zeljko Uzelac, Santhanalakshmi Sundaramurthy et al.

Salvinorin A (SalA), a selective κ-opioid receptor (KOR) agonist, produces dysphoria and pro-depressant like effects. These actions have been attributed to inhibition of striatal dopamine release. The dopamine transporter (DAT) regulates dopamine transmission via uptake of released neurotransmitter. KORs are apposed to DAT in dopamine nerve terminals suggesting an additional target by which...

Permanent suppression of cortical oscillations in mice after adolescent exposure to cannabinoids: receptor mechanisms.

Neuropharmacology November 2014 Sylvina M Raver, Asaf Keller

Marijuana use in adolescence, but not adulthood, may permanently impair cognitive functioning and increase the risk of developing schizophrenia. Cortical oscillations are patterns of neural network activity implicated in cognitive processing, and are abnormal in patients with schizophrenia. We have recently reported that cortical oscillations are suppressed in adult mice that were treated with...

N-acetylcysteine modulates hallucinogenic 5-HT(2A) receptor agonist-mediated responses: behavioral, molecular, and electrophysiological studies.

Neuropharmacology June 1, 2014 Mei-Yi Lee, Chun-Cheng Chiang, Hong‐yi Chiu et al.

N-acetylcysteine (NAC) has been reported to reverse the psychotomimetic effects in the rodent phencyclidine model of psychosis and shown beneficial effects in treating patients with schizophrenia. The effect of NAC has been associated with facilitating the activity of cystine-glutamate antiporters on glial cells concomitant with the release of non-vesicular glutamate, which mainly stimulates...

THE METABOTROPIC GLUTAMATE 2/3 RECEPTOR AGONIST LY379268 COUNTERACTED KETAMINE-AND APOMORPHINE-INDUCED PERFORMANCE DEFICITS IN THE OBJECT RECOGNITION TASK, BUT NOT OBJECT LOCATION TASK, IN RATS

Neuropharmacology May 20, 2014 N. Pitsikas, A. Markou

Experimental evidence indicates that the non competitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine and the mixed dopamine (DA) D1/D2 receptor agonist apomorphine induce schizophrenia-like symptoms in rodents, including cognitive deficits. Activation of Group II metabotropic glutamate 2/3 (mGlu2/3) receptors reduces the excessive glutamate release that is hypothesized to be...

Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia

Neuropharmacology April 3, 2014 David Martin, Danuta Marona‐lewicka, D. E. Nichols et al.

Chronic administration of lysergic acid diethylamide (LSD) every other day to rats results in a variety of abnormal behaviors. These build over the 90 day course of treatment and can persist at full strength for at least several months after cessation of treatment. The behaviors are consistent with those observed in animal models of schizophrenia and include hyperactivity, reduced...

Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.

Neuropharmacology February 1, 2014 Adam L. Halberstadt, Mark A. Geyer 113 citations

N-benzyl substitution markedly enhances the affinity of phenethylamine hallucinogens at the 5-HT(2A) receptor. N-benzyl substituted derivatives of 2,5-dimethoxy-4-iodophenethylamine (2C-I), such as N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBOMe) and N-(2,3-methylenedioxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBMD), have appeared recently as designer drugs, but have...

DOI: 10.1016/j.neuropharm.2013.08.025 (opens in new tab) Full text (opens in new tab) LSD Psychedelic pharmacology 5-ht2a receptor activation Head twitch response

Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Neuropharmacology December 2013 Jenny L Wiley, Julie A. Marusich, Timothy W Lefever et al.

Synthetic indole-derived cannabinoids have become commonly used recreational drugs and continue to be abused despite their adverse consequences. As compounds that were identified early in the epidemic (e.g., naphthoylindoles) have become legally banned, new compounds have appeared on the drug market. Two tetramethylcyclopropyl ketone indoles, UR-144...

DOI: 10.1016/j.neuropharm.2013.07.022 (opens in new tab) Full text (opens in new tab) Abuse liability Delta-9-tetrahydrocannabinol Drug discrimination Synthetic cannabinoids +2

Role of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice.

Neuropharmacology July 2013 Adam L. Halberstadt, Susan B Powell, Mark A. Geyer

The 5-HT₂A receptor mediates the effects of serotonergic hallucinogens and may play a role in the pathophysiology of certain psychiatric disorders, including schizophrenia. Given these findings, there is a need for animal models to assess the behavioral effects of 5-HT₂A receptor activation. Our previous studies demonstrated that the phenylalkylamine hallucinogen and 5-HT₂A/₂C agonist...